Brain tumor

The Glioblastoma Research Organization launches The Lee Project: Using Evolution To Target GBM at The University of Texas MD Anderson Cancer Center

Retrieved on: 
Tuesday, August 11, 2020

HOUSTON, Aug. 11, 2020 /PRNewswire-PRWeb/ --Funded by the Glioblastoma Research Organization, the Laboratory of Dr. Steven Millward at MD Anderson Cancer Center has launched the The Lee Project which focuses on directed evolution of vectors for the treatment of GBM.

Key Points: 
  • HOUSTON, Aug. 11, 2020 /PRNewswire-PRWeb/ --Funded by the Glioblastoma Research Organization, the Laboratory of Dr. Steven Millward at MD Anderson Cancer Center has launched the The Lee Project which focuses on directed evolution of vectors for the treatment of GBM.
  • Glioblastoma remains one of the most lethal cancers, due in large part to its invasiveness and dissemination throughout normal brain tissue.
  • As a result, surgical resection and targeted radiotherapy are extremely challenging in GBM patients.
  • While advances in chemotherapy have dramatically improved patient outcomes in non-CNS tumors, GBM remains refractory to most chemotherapeutics.

CNS Pharmaceuticals to Provide Second Quarter 2020 Business Update on Thursday, August 13, 2020

Retrieved on: 
Tuesday, August 11, 2020

CNS Pharmaceuticals is a biotechnology company specializing in the development of novel treatments for primary and metastatic brain and central nervous system tumors.

Key Points: 
  • CNS Pharmaceuticals is a biotechnology company specializing in the development of novel treatments for primary and metastatic brain and central nervous system tumors.
  • Its lead candidate Berubicin is proposed for the treatment of glioblastoma, a type of brain cancer currently considered incurable, as well as for pancreatic and ovarian cancers, and lymphomas.
  • The Company entered into an intellectual property (IP) agreement with Houston Pharmaceuticals, Inc. and a Purchase Agreement with Reata.
  • CNS undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Monteris Medical Announces Blue Cross Blue Shield of North Carolina Expands Policy Coverage for its NeuroBlate® System Laser Interstitial Thermotherapy for Brain Tumor

Retrieved on: 
Monday, August 3, 2020

PLYMOUTH, Minn., Aug. 3, 2020 /PRNewswire/ -- Monteris Medical , the leader in MRI-guided laser interstitial thermotherapy (LITT or laser ablation), is pleased to announce that health insurance provider Blue Cross Blue Shield of North Carolina (BCBSNC) has updated its medical coverage policy allowing access to the minimally invasive surgical option using laser ablation for brain tumor patients when medically necessary.

Key Points: 
  • PLYMOUTH, Minn., Aug. 3, 2020 /PRNewswire/ -- Monteris Medical , the leader in MRI-guided laser interstitial thermotherapy (LITT or laser ablation), is pleased to announce that health insurance provider Blue Cross Blue Shield of North Carolina (BCBSNC) has updated its medical coverage policy allowing access to the minimally invasive surgical option using laser ablation for brain tumor patients when medically necessary.
  • This decision extends the medical coverage issued by BCBSNC in February 2020, that provides coverage of MRI-guided laser ablation for patients with epilepsy when certain established medical criteria are met.
  • Many patients with brain tumors face situations in which traditional open brain surgery is either not possible, or not the preferred approach.
  • The Monteris NeuroBlate System is the only minimally invasive system that enables a robotic interface for the precise and safe delivery of laser energy.

Ivy Brain Tumor Center and BridgeBio Pharma’s QED Therapeutics Announce Dosing of First Patient in Investigator-Initiated Phase 0/2 Clinical Trial of Infigratinib in Recurrent Glioblastoma

Retrieved on: 
Tuesday, July 28, 2020

Infigratinib is an investigational, orally administered, FGFR1-3 selective tyrosine kinase inhibitor being developed by BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate company QED Therapeutics, Inc.

Key Points: 
  • Infigratinib is an investigational, orally administered, FGFR1-3 selective tyrosine kinase inhibitor being developed by BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate company QED Therapeutics, Inc.
  • Patients with successful tumor penetration will receive infigratinib long-term in a Phase 2 expansion arm of the trial.
  • Infigratinib was one of the most promising agents, said Shwetal Mehta, Ph.D., deputy director of the Ivy Brain Tumor Center.
  • Infigratinib was previously tested in an uncontrolled Phase 2 study for recurrent high-grade gliomas, said Nader Sanai, M.D., director of the Ivy Brain Tumor Center.

Glioblastoma Multiforme (GBM) Market Insights, Epidemiology and Forecast to 2030

Retrieved on: 
Friday, July 24, 2020

The analysis covers Glioblastoma Multiforme (GBM) market uptake by drugs; patient uptake by therapies; and sales of each drug.

Key Points: 
  • The analysis covers Glioblastoma Multiforme (GBM) market uptake by drugs; patient uptake by therapies; and sales of each drug.
  • The publisher performs competitive and market Intelligence analysis of the Glioblastoma Multiforme (GBM) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc.
  • A detailed review of Glioblastoma Multiforme (GBM) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Glioblastoma Multiforme (GBM) market.

NOXXON Announces First Brain Cancer Patient From Second Dose Cohort Reaches 4 Weeks of Treatment With NOX-A12 Combined With Radiotherapy

Retrieved on: 
Friday, July 24, 2020

The Phase 1/2 clinical trial is testing three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy, in newly diagnosed brain cancer patients.

Key Points: 
  • The Phase 1/2 clinical trial is testing three dose regimens of NOX-A12 (200, 400 and 600 mg/week), each combined with external-beam radiotherapy, in newly diagnosed brain cancer patients.
  • The clinical centers participating in the study have now initiated the recruitment of the remaining patients in the second of three escalating dose groups.
  • Once all patients in the second cohort have received a four-weeks treatment of NOX-A12 and radiotherapy, the DSMB will reconvene to determine whether it is safe to proceed to the highest planned dose level of NOX-A12.
  • In September 2019 the company initiated an additional trial with NOX-A12 in brain cancer in combination with radiotherapy.

Wais, Vogelstein, Forman & Offutt Files Lawsuit Against Johns Hopkins Hospital For Negligence Resulting In The Death Of A Two-Year-Old Girl

Retrieved on: 
Tuesday, July 21, 2020

On August 7, 2016, Francesca Webster gave birth to twins Emma and Zoe at Johns Hopkins Hospital via cesarean section.

Key Points: 
  • On August 7, 2016, Francesca Webster gave birth to twins Emma and Zoe at Johns Hopkins Hospital via cesarean section.
  • Healthcare professionals noted that neuroblastoma, a cancer commonly found in the adrenal glands, could not be ruled out and required follow-up testing.
  • "At discharge, we were instructed to follow up with several specialists on Emma's behalf, which we followed through with immediately.
  • "All Johns Hopkins needed to do was inform us of the results from the ultrasound, which they never did.

Ivy Brain Tumor Center and COVID Nurse, Ian Youngblood, Honor Second Annual National Glioblastoma Day on July 22, 2020

Retrieved on: 
Friday, July 17, 2020

PHOENIX, July 17, 2020 /PRNewswire-PRWeb/ -- Nader Sanai, M.D., director of the Ivy Brain Tumor Center at Barrow Neurological Institute and Ian Youngblood, RN, have come together for the second annual Glioblastoma Awareness Day (#GBMDay) on July 22, 2020 to raise national consciousness.

Key Points: 
  • PHOENIX, July 17, 2020 /PRNewswire-PRWeb/ -- Nader Sanai, M.D., director of the Ivy Brain Tumor Center at Barrow Neurological Institute and Ian Youngblood, RN, have come together for the second annual Glioblastoma Awareness Day (#GBMDay) on July 22, 2020 to raise national consciousness.
  • Glioblastoma Awareness Day (GBM Day) is dedicated to increasing public awareness of glioblastoma , the most common and aggressive form of brain cancer.
  • "The need for a bold approach to rapidly identify new, effective therapies for those impacted by this disease is greater than ever."
  • Follow the Ivy Brain Tumor Center on Facebook , Instagram , Twitter and LinkedIn .

Clinical Trials for Evolving Targeted Therapies Fueling Gains for Brain Tumor Therapeutics Market

Retrieved on: 
Wednesday, July 15, 2020

One earlier report from January 2019 said that the Global Brain Tumor Therapeutics Market Will Reach $2.0 Billion by 2023.

Key Points: 
  • One earlier report from January 2019 said that the Global Brain Tumor Therapeutics Market Will Reach $2.0 Billion by 2023.
  • A recent MarketWatch report said: "Increasing incidence of Brain Cancer has resulted in upsurge the demand for brain cancer across the globe which is driving the market.
  • In addition, increased focus on precision medicine is also fueling the global brain tumor therapeutics market Few brain cancer specific drugs and their high cost is acting as a restraint for Brain Tumor therapeutics market.
  • Although various pharmaceutical companies are spending heavily on R&D activities which can bring more treatment options to the market in future."

CNS Pharmaceuticals Completes Drug Product Manufacturing Strategy for Berubicin

Retrieved on: 
Wednesday, July 15, 2020

HOUSTON, July 15, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided an update on the manufacturing strategy for Berubicin drug product, its lead drug candidate for the treatment of glioma brain tumors.

Key Points: 
  • HOUSTON, July 15, 2020 /PRNewswire/ -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided an update on the manufacturing strategy for Berubicin drug product, its lead drug candidate for the treatment of glioma brain tumors.
  • In June, CNS Pharmaceuticals successfully engaged USA-based Pharmaceutics International, Inc., (Pii) and Italian BSP Pharmaceuticals S.p.A., (BSP), respectively, for the production of Berubicin drug product.
  • "Our decision to contract both Pii and BSP represents a key part of our overall strategy to get Berubicin back into clinical trials as soon as possible," stated John Climaco, CEO of CNS Pharmaceuticals.
  • CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system.